Daiichi Sankyo Co Ltd Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/15/2026)
| Balance Sheet | Total Assets | 4,005,390,000,000.00 | ROE | 41.55 % |
| Balance Sheet | Total Equity | 1,664,179,000,000.00 | ROA | 6.49 % |
| Cashflow | Capital Expenditures | -128,365,000,000.00 | P/FCF | -94.23 |
| Cashflow | Free Cash Flow | -50,710,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 77,655,000,000.00 | P/CF | 61.53 |
| Income | Earnings per Share (diluted) | 141.46 | Div. Yield | 2.69 % |
| Income | Net Income | 259,874,000,000.00 | P/E | 18.39 |
| Income | Shares Outstanding | 1,837,131,000.00 | P/B | 2.87 |
| Income | Total Revenue | 2,123,045,000,000.00 | P/S | 2.25 |
Ratios calculated on: 10/14/2026
Company Description
DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe, China and Brazil markets. As of March 31, 2014, it had 100 subsidiaries and four associated companies.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.daiichisankyo.co.jp
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more